Advances in virus-like particle vaccines for filoviruses

Journal of Infectious Diseases

Volumn 204, Issue SUPPL. 3, 2011, Pages

  Warfield, Kelly L ^a   Aman, M Javad ^a  

^a Integrated BioTherapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; EBOLA VACCINE; FREUND ADJUVANT; INACTIVATED VACCINE; MARBURG VIRUS VACCINE; PROTEIN VP40; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS NUCLEOPROTEIN; VIRUS VACCINE; VIRUS VECTOR; WART VIRUS VACCINE;

ANTIBODY RESPONSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL FEATURE; DRUG EFFICACY; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; FILOVIRUS INFECTION; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOSTIMULATION; INNATE IMMUNITY; MARBURG HEMORRHAGIC FEVER; MARBURG VIRUS; NONHUMAN; PAPILLOMAVIRUS INFECTION; PARAINFLUENZA VIRUS; PRIORITY JOURNAL; PROTEIN DOMAIN; REPLICON; REVIEW; VACCINATION; VACCINE PRODUCTION; VESICULAR STOMATITIS VIRUS; VIREMIA; VIRION; VIRUS CELL INTERACTION; VIRUS INHIBITION; VIRUS LIKE AGENT; VIRUS REPLICATION;

ANIMALS; FILOVIRIDAE; FILOVIRIDAE INFECTIONS; HEMORRHAGIC FEVERS, VIRAL; HUMANS; VACCINES, VIRUS-LIKE PARTICLE; VIRAL VACCINES;

EID: 80054771708     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir346     Document Type: Review

References (79)

1. Hevey M, Negley D, Vanderzanden L, et al. Marburg virus vaccines, comparing classical and new approaches. Vaccine 2002; 20:586-93.
2. Ignat'ev GM, Strel'tsova MA, Agafonov AP, Zhukova NA, Kashentseva EA, Vorob'eva MS. [The immunity indices of animals immunized with the inactivated Marburg virus after infection with homologous virus]. Vopr Virusol 1994; 39:13-7.
3. Ignatev GM, Agafonov AP, Strel'tsova MA, et al. A comparative study of the immunological indices in guinea pigs administered an inactivated Marburg virus. Vopr Virusol 1991; 36:421-3.
4. Ignatyev GM, Agafonov AP, Streltsova MA, Kashentseva EA. Inactivated Marburg virus elicits a nonprotective immune response in Rhesus monkeys. J Biotechnol 1996; 44:111-8. (Pubitemid 26056569)
5. Geisbert TW, Pushko P, Anderson K, Smith J, Davis KJ, Jahrling PB. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis 2002; 8:503-7. (Pubitemid 34533328)
6. Lupton HW, Lambert RD, Bumgardner DL, Moe JB, Eddy GA. Inactivated vaccine for Ebola virus efficacious in guineapig model. Lancet 1980; 2:1294-5. (Pubitemid 11197323)
7. Rao M, Bray M, Alving CR, Jahrling P, Matyas GR. Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(1) T cells. J Virol 2002; 76:9176-85. (Pubitemid 34919876)
8. Geisbert T, Jahrling P. Towards a vaccine against Ebola virus. Expert Rev Vaccines 2003; 2(6):777-89. (Pubitemid 37541564)
9. Mikhailov VV, Borisevich IV, Chernikova NK, Potryvaeva NV, Krasnianskii VP. [The evaluation in hamadryas baboons of the possi-bility for the specific prevention of Ebola fever]. Vopr Virusol 1994; 39:82-4.
10. Hevey M, Negley D, Geisbert J, Jahrling P, Schmaljohn A. Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants. Virology 1997; 239:206-16. (Pubitemid 28027084)
11. Riemenschneider J, Garrison A, Geisbert J, et al. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine 2003; 21:4071-80. (Pubitemid 37345136)
12. Mellquist-Riemenschneider JL, Garrison AR, Geisbert JB, et al. Comparison of the protective efficacy of DNA and baculovirus-derived protein vaccines for EBOLA virus in guinea pigs. Virus Res 2003; 92:187-93. (Pubitemid 36398464)
13. Hart MK. Vaccine research efforts for filoviruses. Int J Parasitol 2003; 33:583-95. (Pubitemid 36638539)
14. Garbutt M, Liebscher R, Wahl-Jensen V, et al. Properties of replicationcompetent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 2004; 78:5458-65. (Pubitemid 38581495)
15. Pushko P, Geisbert J, Parker M, Jahrling P, Smith J. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J Virol 2001; 75:11677-85. (Pubitemid 33063259)
16. Pushko P, Bray M, Ludwig GV, et al. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine 2000; 19:142-53. (Pubitemid 30618964)
17. Wilson JA, Hart MK. Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein. J Virol 2001; 75:2660-4. (Pubitemid 32185029)
18. Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 1998; 251:28-37. (Pubitemid 28527716)
19. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000; 408:605-9.
20. Nabel GJ. Vaccine for AIDS and Ebola virus infection. Virus Res 2003; 92:213-7. (Pubitemid 36398468)
21. Sullivan NJ, Geisbert TW, Geisbert JB, et al. Accelerated vaccination for Ebola virus hemorrhagic fever in non-human primates. Nature 2003; 424:681-4. (Pubitemid 36987993)
22. Bukreyev A, Rollin PE, Tate MK, et al. Successful topical respiratory tract immunization of primates against Ebola virus. J Virol 2007; 81:6379-88. (Pubitemid 46878044)
23. Bukreyev A, Yang L, Zaki SR, et al. A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethaldose Ebola virus challenge. J Virol 2006; 80:2267-79. (Pubitemid 43271533)
24. Buonaguro L, Tornesello ML, Buonaguro FM. Virus-like particles as particulate vaccines. Curr HIV Res 2010; 8:299-309.
25. Noad R, Roy P. Virus-like particles as immunogens. Trends Microbiol 2003; 11:438-44. (Pubitemid 37101484)
26. Naslund J, Lagerqvist N, Habjan M, et al. Vaccination with virus-like particles protects mice from lethal infection of Rift Valley fever virus. Virology 2009; 385:409-15.
27. Conner ME, Zarley CD, Hu B, et al. Virus-like particles as a rotavirus subunit vaccine. J Infect Dis 1996; 174(Suppl 1):S88-92. (Pubitemid 26293127)
28. Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Estes MK. Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin Immunol 2003; 108:241-7. (Pubitemid 37117370)
29. Bavari S, Bosio CM, Wiegand E, et al. Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J Exp Med 2002; 195:593-602. (Pubitemid 34461504)
30. Warfield KL, Bosio CM, Welcher BC, et al. Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci U S A 2003; 100:15889-94. (Pubitemid 38021085)
31. Swenson DL, Warfield KL, Kuehl K, et al. Generation of Marburg viruslike particles by co-expression of glycoprotein and matrix protein. FEMS Immunol Med Microbiol 2004; 40:27-31. (Pubitemid 38083355)
32. Noda T, Sagara H, Suzuki E, Takada A, Kida H, Kawaoka Y. Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol 2002; 76:4855-65. (Pubitemid 34441691)
33. Warfield KL, Posten NA, Swenson DL, et al. Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents. J Infect Dis 2007; 196(Suppl 2):S421-9. (Pubitemid 351417290)
34. Kallstrom G, Warfield KL, Swenson DL, et al. Analysis of Ebola virus and VLP release using an immunocapture assay. J Virol Methods 2005; 127:1-9. (Pubitemid 40704631)
35. Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, Bavari S. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 2007; 196(Suppl 2): S430-7. (Pubitemid 351417291)
36. Swenson DL, Warfield KL, Larsen T, Alves DA, Coberley SS, Bavari S. Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses. Expert Rev Vaccines 2008; 7:417-29. (Pubitemid 351656813)
37. Basler CF, Mikulasova A, Martinez-Sobrido L, et al. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol 2003; 77:7945-56. (Pubitemid 36792791)
38. Reid SP, Leung LW, Hartman AL, et al. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol 2006; 80:5156-67.
39. Valmas C, Grosch MN, Schumann M, et al. Marburg virus evades interferon responses by a mechanism distinct from ebola virus. PLoS Pathog 2010; 6:e1000721.
40. Harty RN, Brown ME, Wang G, Huibregtse J, Hayes FP. A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding. Proc Natl Acad Sci U S A 2000; 97:13871-6.
41. Han Z, Boshra H, Sunyer JO, Zwiers SH, Paragas J, Harty RN. Biochemical and functional characterization of the Ebola virus VP24 protein: implications for a role in virus assembly and budding. J Virol 2003; 77:1793-800. (Pubitemid 36109991)
42. Licata JM, Johnson RF, Han Z, Harty RN. Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles. J Virol 2004; 78:7344-51. (Pubitemid 38915880)
43. Jasenosky LD, Kawaoka Y. Filovirus budding. Virus Res 2004; 106:181-8. (Pubitemid 39572963)
44. Jasenosky LD, Neumann G, Lukashevich I, Kawaoka Y. Ebola virus VP40-induced particle formation and association with the lipid bilayer. J Virol 2001; 75:5205-14. (Pubitemid 32448543)
45. Panchal RG, Ruthel G, Kenny TA, et al. In vivo oligomerization and raft localization of Ebola virus protein VP40 during vesicular budding. Proc Natl Acad Sci U S A 2003; 100:15936-41. (Pubitemid 38021093)
46. Hoenen T, Biedenkopf N, Zielecki F, et al. Oligomerization of Ebola virus VP40 is essential for particle morphogenesis and regulation of viral transcription. J Virol 2010; 84:7053-63.
47. Licata JM, Simpson-Holley M, Wright NT, Han Z, Paragas J, Harty RN. Overlapping motifs (PTAP and PPEY) within the Ebola virus VP40 protein function independently as late budding domains: involvement of host proteins TSG101 and VPS-4. J Virol 2003; 77:1812-9. (Pubitemid 36109993)
48. Yamayoshi S, Kawaoka Y. Mapping of a region of Ebola virus VP40 that is important in the production of virus-like particles. J Infect Dis 2007; 196(Suppl 2):S291-5. (Pubitemid 351417274)
49. Timmins J, Schoehn G, Ricard-Blum S, et al. Ebola virus matrix protein VP40 interaction with human cellular factors Tsg101 and Nedd4. JMol Biol 2003; 326:493-502. (Pubitemid 36279343)
50. Dessen A, Forest E, Volchkov V, Dolnik O, Klenk HD, Weissenhorn W. Crystallization and preliminary X-ray analysis of the matrix protein from Ebola virus. Acta Crystallogr D Biol Crystallogr 2000; 56:758-60. (Pubitemid 30392573)
51. Ruigrok RW, Schoehn G, Dessen A, et al. Structural characterization and membrane binding properties of the matrix protein VP40 of Ebola virus. J Mol Biol 2000; 300:103-12.
52. Liu Y, Cocka L, Okumura A, Zhang YA, Sunyer JO, Harty RN. Conserved motifs within Ebola and Marburg virus VP40 proteins are important for stability, localization, and subsequent budding of virus-like particles. J Virol 2009; 84:2294-303.
53. Kolesnikova L, Bamberg S, Berghofer B, Becker S. The matrix protein of Marburg virus is transported to the plasma membrane along cellularmembranes: exploiting the retrograde late endosomal pathway. J Virol 2004; 78:2382-93. (Pubitemid 38228931)
54. Kolesnikova L, Bugany H, Klenk HD, Becker S. VP40, the matrix protein of Marburg virus, is associated with membranes of the late endosomal compartment. J Virol 2002; 76:1825-38. (Pubitemid 34094630)
55. McCarthy SE, Johnson RF, Zhang YA, Sunyer JO, Harty RN. Role for amino acids 212KLR214 of Ebola virus VP40 in assembly and budding. J Virol 2007; 81:11452-60. (Pubitemid 47536115)
56. Warfield KL, Swenson DL, Negley DL, Schmaljohn AL, Aman MJ, Bavari S. Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection. Vaccine 2004; 22:3495-502. (Pubitemid 39078769)
57. Sun Y, Carrion R Jr, Ye L, et al. Protection against lethal challenge by Ebola virus-like particles produced in insect cells. Virology 2009; 383:12-21.
58. Warfield KL, Olinger G, Deal EM, et al. Induction of humoral and CD81 T cell responses are required for protection against lethal ebola virus infection. J Immunol 2005; 175:1184-91. (Pubitemid 41095006)
59. Swenson DL, Warfield KL, Negley DL, Schmaljohn A, Aman MJ, Bavari S. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine 2005; 23:3033-42. (Pubitemid 40462443)
60. Ye L, Lin J, Sun Y, et al. Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies. Virology 2006; 351:260-70. (Pubitemid 44108063)
61. Bosio CM, Moore BD, Warfield KL, et al. Ebola and Marburg virus-like particles activate human myeloid dendritic cells. Virology 2004; 326:280-7. (Pubitemid 39078259)
62. Warfield KL, Bradfute SB, Wells J, et al. Development and characterization of a mouse model for Marburg hemorrhagic fever. J Virol 2009; 83:6404-15.
63. Warfield KL, Jaax NK, Deal EM, Swenson DL, Larsen T, Bavari S. Viral hemorrhagic fevers. In: Swearengen JR ed: Biodefense: research methodology and animal models. Boca Raton, FL: Taylor & Francis Group, 2005: 227-58.
64. Bente D, Gren J, Strong JE, Feldmann H. Disease modeling for Ebola and Marburg viruses. Dis Model Mech 2009; 2:12-7.
65. Waite DC, Jacobson EW, Ennis FA, et al. Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. Vaccine 2001; 19:3957-67. (Pubitemid 32566320)
66. Feldmann H, Jones S, Klenk HD, Schnittler HJ. Ebola virus: from discovery to vaccine. Nat Rev Immunol 2003; 3:677-85. (Pubitemid 37328670)
67. Geisbert TW, Hensley LE, Larsen T, et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 2003; 163:2347-70. (Pubitemid 37466478)
68. Bradfute SB, Braun DR, Shamblin JD, et al. Lymphocyte death in a mouse model of Ebola virus infection. J Infect Dis 2007; 196(Suppl 2): S296-304. (Pubitemid 351417275)
69. Geisbert TW, Hensley LE, Gibb TR, Steele KE, Jaax NK, Jahrling PB. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest 2000; 80:171-86. (Pubitemid 30120970)
70. Galluzzi L, Kepp O, Morselli E, et al. Viral strategies for the evasion of immunogenic cell death. J Intern Med 2010; 267:526-42.
71. Mahanty S, Hutchinson K, Agarwal S, McRae M, Rollin PE, Pulendran B. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J Immunol 2003; 170:2797-801. (Pubitemid 36302147)
72. Bosio CM, Aman MJ, Grogan C, et al. Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis 2003; 188:1630-8. (Pubitemid 38010672)
73. Geisbert TW, Young HA, Jahrling PB, et al. Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol 2003; 163:2371-82. (Pubitemid 37474154)
74. Wahl-Jensen V, Kurz SK, Hazelton PR, et al. Role of ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages. J Virol 2005; 79:2413-9. (Pubitemid 40204596)
75. Daddario-DiCaprio KM, Geisbert TW, Stroher U, et al. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 2006; 367:1399-404.
76. Feldmann H, Jones SM, Daddario-DiCaprio KM, et al. Effective postexposure treatment of Ebola infection. PLoS Pathog 2007; 3:e2.
77. Geisbert TW, Daddario-DiCaprio KM, Williams KJ, et al. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan ebola hemorrhagic fever in nonhuman primates. J Virol 2008; 82:5664-8. (Pubitemid 351705275)
78. Warfield KL, Perkins JG, Swenson DL, et al. Role of natural killer cells in innate protection against lethal ebola virus infection. J Exp Med 2004; 200:169-79. (Pubitemid 38982176)
79. Kim S, Iizuka K, Aguila HL, Weissman IL, Yokoyama WM. In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc Natl Acad Sci U S A 2000; 97:2731-6. (Pubitemid 30159240)